Publication | Closed Access

Increased potency of BioThrax® anthrax vaccine with the addition of the C-class CpG oligonucleotide adjuvant CPG 10109

VaccinationVaccine DevelopmentCpg 10109MedicineBiothrax® Anthrax VaccineC-class CpgImmunologyTherapeutic VaccineVaccine DesignPolyvalent VaccinePrecision Vaccinology